Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 1,501–1,600 of 1,639
Endocrine regulation of cardiac fibrosis: implications for HFpEF
Chaturvedi, R., & Atreja, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911465
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
“In STEP-HFpEF, semaglutide 2.4 mg improved heart failure-related symptoms, physical limitations, exercise function, inflammation, and body weight compared with placebo in patients with HFpEF and obesity [13].”
InfluentialHalavina, K., Bartko, P. E., & Nitsche, C. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3261
Tsai, Y., Lin, H.-T., Liu, Y.-F., Chang, R., & Wu, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s612622
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
Aguado, B., Lacoste-Palasset, T., Ruffenach, G., Bauer, F., Savale, L., Humbert, M. J. C., Montani, D., & Antigny, F. (2025) · ERJ Open Research · doi:10.1183/23120541.01479-2025
“Mechanistic investigations revealed that these effects were mediated through upregulation of the NO pathway and downregulation of endothelin-1 expression, leading to improved pulmonary artery dilation and reduced pulmonary vascular fibrosis [88].”
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
Seeing Beyond GLP‐1: A Systems View of Sustainable Obesity Care
Mui, Y., Winkler, M. R., Ramsing, B., Palmer, A., & Altema-Johnson, D. (2026) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70300 · Cited by 1
“Viewed through a temporal lens, the relatively quick results of GLP‐1 therapies contrast sharply with the slow work of necessary lifestyle change [43, 44].”
Bal, H. S., Nayak, A., Pampana, A., Malay, S., Upadhyaya, A., Vekariya, N., Arora, G., & Arora, P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101451
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown benefit in HFpEF [4].”
Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction
Hida, Y., Imamura, T., & Kinugawa, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124831
“…that high-dose subcutaneous semaglutide significantly improved quality of life, exercise capacity, and body weight in obese patients with HFpEF and reduced natriuretic peptides and C-reactive protein (CRP), suggesting favorable effects on cardiac congestion and systemic inflammation [13–15].”
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.70008
Targeting the cardiohepatic–metabolic axis: GLP‐1–based and incretin multi‐agonist therapies in MASH
Zhang, Y. W., & Hu, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70828
Low-carbohydrate Ketogenic Diet in Patients with Heart Failure: Signals, Safeguards, and Next Steps
Singar, S., Khan, M. S., & Carbone, S. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.10.001
Vallapuri, G. S., Jariwala, P. V., Gude, D., Kumar, K. B., & Jangam, S. K. (2026) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_92_25
Burr, E. F., Roytman, M., Poirier, É., Kolbuszewska, M. T., Pfaus, J. G., Komisaruk, B. R., Goldstein, I., & Rubin, R. S. (2025) · Sexual Medicine · doi:10.1093/sexmed/qfaf073 · Cited by 3
Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF
Ceravolo, R., Lucà, F., Gulizia, M. M., Nardi, F., Grimaldi, M., & Gelsomino, S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.06.015
Strugała, N., Kostrzewski, M., Noworolska, M., Wojtaszkiewicz, D., Skrzeczyna, J., Sapała, E., Bednarska, K., Zurek, J., Wiśniewska, M., Bulenda, M., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6003
Larina, V. N. (2025) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2025-448-459 · Cited by 1
El‐Sheikh, M., Sillassen, C. D. B., Wisborg, F. D., Hove, J. D., Dirksen, C., Lee, M. M. Y., Jakobsen, J. C., & Grand, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103668 · Cited by 2
“38 39 In addition, in patients with HFpEF and obesity, tirzepatide reduced the risk of cardiovascular death or worsening HF, mainly by lowering HF events.”
Continuity of care in obesity clinical care
Lesmes, I. B., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501658 · Cited by 1
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Yang, C.-C., Hung, C., Chien, C., Hsieh, Y.-W., Huang, W.-M., Yun, C., & Cury, R. C. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1820542
Tepetes, N.-I., Filippatos, C., Athanasopoulos, S., Konstantaki, C., Batziou, P., Soranidis, A., Kostakou, P., Stamatelopoulos, K., & Briasoulis, Α. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002139
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Clinical Perspectives for Diagnosis and Treatment of Diabetic CardiomyopathyPreprint
Chen, D., Sindone, A. P., Huang, M. L. H., Peter, K., & Jenkins, A. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5072684
Yagi, K., Chujo, D., Usui, I., Liu, J., Nohara, A., Enkaku, A., Takikawa, A., Honoki, H., Fujisaka, S., Origasa, H., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.103551 · Cited by 1
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Smolderen, K. G. E., Mena‐Hurtado, C., Divino, V. M., Zhao, Z., CHEN, Y., Boland, J., Song, J., Iyer, P., Knop, F. K., Nanna, M. G., et al. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.05.004
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
“Coverage policies that restrict treatment only to extreme BMI categories may miss patients with established CVD, CKD or HFpEF who have substantial cardiometabolic risk at lower BMI (6 – 8 Persistence is a clinical skill as much as a patient behaviour (45, 49, 58).”
InfluentialShirmohamadi, E., Ghasemloo, N., Ebrahimi, N., Mohammadzadeh, N., Ehtemami, A., Babaei, M., & Fardoost, S. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70311
Karanxha, J., Guni, M., Xhabija, N., Dede, M., Mone, I., & Prifti, E. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134773
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
“Meta-analyses [49,50] and large CVOTs [2–8] support a coherent class impact on MACE, hospitalization for heart failure, and composite renal outcomes.”
Metabolite sensing in cardiometabolic HFpEF: mechanisms and therapeutic perspectives
Fan, Y., Wang, X., Ai, S., Zhang, S., Zhu, Y., & Jiang, W. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113432
Goshe, M., Singh, S., Zameer, R., Ali, J., Kumari, N., & Das, M. (2026) · Cureus · doi:10.7759/cureus.114404
“Semaglutide produced a placebo-adjusted improvement in 6MWD of 14.6 m at 20 weeks and 17.1 m at 52 weeks, alongside improvements in KCCQ-CSS, body weight, C-reactive protein, NT-proBNP, and the hierarchical composite outcome [13,19].”
InfluentialFrom evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease
Maggioni, A. P., Orso, F., Lucci, D., Luca, L. D., & Colivicchi, F. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134646
Concurrent diabetes and heart failure: revisiting epidemiological and clinicopathological interplay
Balagopalan, J. P., Bansal, S., Bhattacharyya, A., Zargar, A. H., Dani, S., Taraphder, A., Almeida, A. F., Deka, N., Jain, S., & Swami, O. C. (2025) · Diabetology International · doi:10.1007/s13340-025-00855-5
“The study found considerable improvement in HF symptoms after 52 weeks of treatment with semaglutide (2.4 mg once weekly) [ 66].”
InfluentialMalik, A., & Aleksova, N. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.128
Alhazmi, A. M., Alayoubi, F., Mufti, R. E., & Albulushi, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103423
Therapieprinzipien bei Adipositas – was ändert sich in der aktualisierten S3-Leitlinie?
Rohmann, N., Hollstein, T., & Laudes, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01900-w · Cited by 1
Balla, S., Chakraborti, K., Jain, N., Ruske, J., & Shah, K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.016
Pan, Y., Li, W.-H., Zhang, W., Ma, W., & Sun, H. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00599-x · Cited by 1
“In obesity-related HFpEF, the main signal was improvement in patient-reported HF symptoms, physical limitation, exercise capacity and body weight, including in patients with type 2 diabetes [258, 259].”
Seth, S., Chopra, V., Sinha, N., Nair, T., Böhm, M., Sawhney, J. P. S., Oomman, A., Jaswal, A., Gopi, A., Rao, S., et al. (2026) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_64_26
Self-citationMilluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02189-x
Picinin, V. D., Balbinott, L. T., Spolaor, A., & Barachini, A. P. (2025) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i2.2025.1731
Iwakura, K., Okamura, A., Iwanaga, Y., Koyama, Y., Tanaka, N., Okada, M., Seo, M., Yamada, T., Yano, M., Hayashi, T., et al. (2025) · medRxiv · doi:10.1101/2025.05.13.25327566
Oliveira-Gomes, D. D., de Majo, A. M., Ardila-Delgado, A. D., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01395-2
“These find - ings suggest a potential role for semaglutide in addressing both metabolic and functional aspects of obesity-related HFpEF [ 48].”
Diastolic dysfunction and diabetes: the DIADAD study—a retrospective cohort study from Liverpool
Wali, L., Abbara, M. A., Ekhelikar, S., Pilling, J., Albouaini, K., & Murray, S. W. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag079
Kishimori, T., Kato, T., Wada, A., Tani, A., YAMAJI, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.026 · Cited by 3
Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets
Cami, E., Verghote, E., Pecetto, E., González, A., Bråkenhielm, E., Jones, E. A. V., & van Empel, V. P. M. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00745-0 · Cited by 2
“Indeed, the STEP-HFpEF trial demonstrated that sema-glutide improved HF-related symptoms, body weight, and reduced inflammatory biomarkers, including CRP and NT-proBNP [134].”
Taşkan, H., Eşki, S., Eravcı, Ö., İliş, D., & Çakal, S. (2026) · Bulletin of Cardiovasculer Academy · doi:10.4274/kvbulten.galenos.2026.08370
Beyond BMI: why heart failure trials must quantify adiposity, not just obesity
Bayés‐Genís, A., & Schiattarella, G. G. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag046
Distinct Exercise Response Patterns in Patients With Heart Failure With Preserved Ejection Fraction
Schutter, S. D., Pugliese, N. R., Meems, L. M. G., Ferreira, S. M., Biase, N. D., Punta, L. D., Masi, S., Stassen, J., Herbots, L., Claessen, G., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.050524
“46 Similarly, tirzepatide reduced cardiovascular events and improved health status.”
Time to Rethink our Approach to Guidelines? International Cascade Guidelines for Heart Failure
Atherton, J. J., Sindone, A. P., & Coats, A. J. S. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.093
Mavraganis, G., Fragoulis, C., Georgiopoulos, G. A., Mavromoustakou, K., Dimitriadis, K. P., Aznaouridis, K. A., Chrysohoou, C. A., Stamatelopoulos, K. S., & Tsioufis, K. P. (2026) · Medicina · doi:10.3390/medicina62071222
Less water, not less fat: empagliflozin unloads myocardial volumes in obese patients
Tortigue, M., Paillard, M., & Mewton, N. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag110
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
Body Composition in Heart Failure: A Phenotype-Informed Framework for Assessment and Management
van der Hoef, C. C. S., ter Maaten, J. M., Meems, L. M. G., Gorter, T. M., Tromp, J., van Veldhuisen, D. J., & Voors, A. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.08.018
Lǐ, Y., Lv, C., Cao, L., Sun, L., & Ma, Y. (2026) · Biomedical Reports · doi:10.3892/br.2026.2165
“The exclusion of the three STEP trials led by the Wilding/Wadden group (n=2,3,5) or the two HFpEF trials led by Kosiborod et al (22,23) yielded pooled ORs of 0.70 (95% CI, 0.53‑0.93) and 0.66 (0.49‑0.90), respectively‑both including the main estimate‑indicating minimal institution‑ level effect.”
InfluentialAdipose Tissue, Natriuretic Peptides, and HFpEF: Clinical Implications of the Obesity Paradox
Wilk, M. M., & Gajewski, P. (2026) · Biomedicines · doi:10.3390/biomedicines14061305 · Cited by 1
“The first of them is glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), which have demonstrated significant effects in reducing body weight, improving cardiometabolic parameters, and exerting insulin-sensitizing and anti-inflammatory effects [64,65,68].”
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146170 · Cited by 1
“…improve renal oxygen handling, and alter cellular energetics [37,43–45 , 68– GLP-1 receptor agonists modulate multiple components of residual risk through receptor-mediated cAMP generation, protein kinase A activation, and signaling via the exchange protein directly activated by cAMP [84,85,89–91].”
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
Al-Nusair, M., Khurana, S., Eysha, M., Elchouemi, M., & Zaki, I. H. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02087-z
Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction
Conte, C., Sumithran, P., le Roux, C. W., Miras, A. D., & Gaal, L. V. (2026) · Obesity Reviews · doi:10.1111/obr.70229
Was ist gesichert in der medikamentösen Therapie der Herzinsuffizienz?
Soltani, S., & Bauersachs, J. K. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01998-y
Schnittstellen in der kardiovaskulären Medizin
Maack, C. (2024) · Herz · doi:10.1007/s00059-024-05238-1
Psychosocial Stressors and Heart Failure Risk Among Black Women in the US
Davis, D. N., Aghi, A., Gajjar, P., Miller, P., Holder, E. X., Nayor, M. G., & Palmer, J. R. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29320
Managing Obesity in Heart Failure Patients: Current Evidence and Strategies
Sharma, S., Giri, G. K., Desai, A., Ruiz, J., Gomez, V., & GOSWAMI, R. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.016
Pivotal Trials in Heart Failure in 2024—Putting Evidence into Clinical Practice!
Thandi, P., Pradhan, A. K., & Behera, S. K. (2025) · International Journal of Angiology · doi:10.1055/a-2624-5735
Velardi, V., Luca, F. D., Fabris, B., et al. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01426-7
Bozkurt, B. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102631
Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
Sattar, N. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00013-6
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.95.108
A propensity score-integrated win ratio method for placebo borrowing
Chen, Y., Sonksen, M., Wang, T., Feng, Y., & Song, J. J. (2026) · Statistical Methods in Medical Research · doi:10.1177/09622802261478737
“17 The WR analysis has also been applied in many therapeutic areas, including CV disease, 18 heart failure, 19,20 COVID-19-related thrombosis, 21 and chronic kidney disease.”
Contrasting obesity: is something missing here? Comment
Vincenzo, A. D., Vettor, R., & Rossato, M. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03646-z
“Of course, we do not have to overestimate the impact of these drugs on the globesity , but at the same time we should not underestimate their potential, as they also seem promising in the treatment of different conditions such as heart failure [4], and even neurodegenerative disorders [5].”
Mejia, C. A. U., Soto, C. V. S., Robalino, J., Hernández, M., Bretón, M. B. S., Garcia-Vasquez, E. A., Rocha, P., Brambila, L. M. P., Morales, S., Romo, M. M., et al. (2025) · Cureus · doi:10.7759/cureus.85250 · Cited by 1
“Each article was assessed for risk of bias [15,16]; of the two articles evaluated, both exhibited a low risk of bias [6,17].”
InfluentialPagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
The Year in Cardiology—Practice Changing Trials from European Society of Cardiology Congress 2023
Pradhan, A. K., Tripathi, U. C., & Singh, A. (2024) · International Journal of Angiology · doi:10.1055/s-0044-1788893
Finerenone after FINEARTS-HF: evidence boundaries and implementation in heart failure with LVEF ≥40%
Feng, S., & Jin, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1880045
“Semaglutide 2.4 mg improved symptoms, physical limitations, body weight, 6 min walk distance, and inflammation in STEP-HFpEF and STEP-HFpEF DM, but these were primarily symptom and function trials rather than hard-outcome trials (55, 56).”
InfluentialLeading the Charge in Obesity Management: A Call to Action for Cardiovascular Nursing
Bryant, E., Laing, K., Langdon, K. D., Salisbury, H., & Villavaso, C. D. (2025) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000001192
Milieu-dependent small-cavity diabetic HFpEF in the DIO-STZ model
Zhu, H., & Zhou, Y. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00330.2026
Finerenone in HFmrEF and HFpEF: modest gains in patient quality of life
Park, J. J., & Störk, S. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag084
Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update?
Gjermeni, D., Alexander, K. M., Januzzi, J. L., & Mahaffey, K. W. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00462-8
“The true representation of patients with amyloidosis in major HF clinical trials, particularly in trials of heart failure with preserved ejection fraction (HFpEF), remains largely unknown [6, 7].”
Femoral Plaque Burden and Left Ventricular–Arterial Coupling in Patients with Chronic Heart Failure
Genkel, V. V., Ershov, S. V., Лебедев, Е. В., Zaripova, Y., & Иосифович, Ш. И. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15052014
Updates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Use of Pharmacotherapy in Obesity Management
Wei, T. K. (2024) · The Singapore Family Physician · doi:10.33591/sfp.49.9.u5
Liu, C., Hui, Q., Linchangco, G. V., Dabbs‐Brown, A., Zhou, J. J., Joseph, J., Reaven, P. D., Rhee, M. K., Djoussé, L., Cho, K., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350615
Achanta, A., Belak, L., Ritchie, C. S., Januzzi, J. L., & Wasfy, J. H. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.033
How difficult is the diagnosis of heart failure with preserved ejection fraction
Cesari, A., Sacco, A., & Oliva, F. G. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag040
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
Al-Shudifat, M., Sumra, B., Kocherry, C., Shamim, H., Jhakri, K., & Khan, S. (2025) · Cureus · doi:10.7759/cureus.78570 · Cited by 5
“Participants in the STEP HFpEF trial who received semaglutide showed significant reductions in weight and in C-reactive protein (CRP), demonstrating that GLP-1 receptor agonists improve both functional outcomes and quality of life through weight-dependent and anti-inflammatory mechanisms [23].”
Malmborg, M. W., El-Chouli, M. H., Andersen, C. F., Elmegaard, M., Garred, C. H., Zahir, D., Butt, J. H., Christensen, D. M., Nouhravesh, N., Fosbøl, E. L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03062-3
“Associations between body mass index, treated as a continuous variable, and the primary and secondary outcomes using restricted cubic splines in Cox proportional-hazards models.”
Self-citationSkacel, T. P., Saleh, N. R., Pavelec, C. M., Quach, K., Bradley, L. A., Bresticker, J. E., Patel, A. R., Wolf, M. J., & Epstein, F. H. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101554 · Cited by 1
Macklin, L., & Simpson, M. (2024) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvae140
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Patoulias, D., Karagiannidis, E., Maragkoudakis, S., Alexanian, I. P., Papadopoulos, C., & Fragakis, N. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.08.007 · Cited by 1
Huang, Y., Li, P.-Y., Liu, K.-W., Li, P., Chen, S.-C., Chen, J., Meyerowitz‐Katz, G., Huang, J.-Y., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261490985
Llàcer, P., Marcos, M. C., Nuñez, J., Perez-Belmonte, L. M., Pérez-Silvestre, J., Marteles, M. S., & Colet, J. C. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502520
Król, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208
Peralta, V. B. T. (2026) · Cirugía Cardiaca en México · doi:10.35366/122230
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.